Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics
Latest Information Update: 13 May 2022
At a glance
- Drugs Fluticasone furoate (Primary) ; Umeclidinium/vilanterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Diagnostic use
- 03 May 2022 Planned End Date changed from 31 Jan 2022 to 31 Jan 2025.
- 03 May 2022 Planned primary completion date changed from 31 Dec 2020 to 31 Dec 2024.
- 28 Feb 2017 Planned primary completion date changed from 1 Jan 2022 to 31 Dec 2020.